{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:49:28Z","timestamp":1782121768525,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Sacizuzumab Tirumotecan is a novel antibody-drug conjugate targeting TROP2 glycoprotein, which is highly expressed across malignant cells. Sacizuzumab Tirumotecan has already demonstrated promising clinical activity in combating breast and lung cancer, and it is currently under evaluation for use against gynecologic malignancies. This review aims to highlight the therapeutic potential of Sacituzumab Govitecan in gynecologic malignancies and to summarize the most recent evidence supporting its clinical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Ongoing phase III trials of Sacituzumab Tirumotecan include cervical, ovarian, and endometrial cancers. Preliminary safety data of Sacituzumab Tirumotecan indicates a manageable toxicity profile, with the most commonly reported adverse events including hematologic toxicity, oral mucositis, and alopecia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Mature data from Phase III trials are anticipated to clarify the impact of Sacituzumab Tirumotecan on overall survival, progression-free survival, and objective response rates. Additionally, biomarker analyses may enhance patient selection strategies and refine prognostic assessment in gynecologic oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-026-01806-2","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:09:51Z","timestamp":1782119391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9882-9478","authenticated-orcid":false,"given":"Amalia A.","family":"Sofianidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Panagodimou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Kalampokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Georgakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"1806_CR1","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1016\/j.lanogw.2025.10.001","volume":"1","author":"B Levy","year":"2025","unstructured":"Levy B, Schwarz N, Vaknin Z, Segev Y, Rosengarten O, Perets R, Levy T, Safra T, Magen Z, Fotopoulou C. Increasing Incidence of Endometrial Cancer Demands Global Action. Lancet Obstet Gynaecol Womens Health. 2025;1:e158\u20139. https:\/\/doi.org\/10.1016\/j.lanogw.2025.10.001.","journal-title":"Lancet Obstet Gynaecol Womens Health"},{"key":"1806_CR2","doi-asserted-by":"publisher","first-page":"04155","DOI":"10.7189\/jogh.14.04155","volume":"14","author":"B Zhu","year":"2024","unstructured":"Zhu B, Gu H, Mao Z, Beeraka NM, Zhao X, Anand MP, Zheng Y, Zhao R, Li S, Manogaran P, et al. Global Burden of Gynaecological Cancers in 2022 and Projections to 2050. J Glob Health. 2024;14:04155. https:\/\/doi.org\/10.7189\/jogh.14.04155.","journal-title":"J Glob Health"},{"key":"1806_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1806_CR4","unstructured":"American Cancer Society. Cervical cancer survival rates: Cancer 5 year survival rates. Accessed [December 15, 2025]. Available at: https:\/\/www.Cancer.Org\/Cancer\/Types\/Cervical-Cancer\/Detection-Diagnosis-Staging\/Survival.Html"},{"key":"1806_CR5","unstructured":"American Cancer Society. Ovarian cancer survival rates. Accessed [December 15, 2025]. Available at: Https:\/\/Www.Cancer.Org https:\/\/www.Cancer\/Types\/Ovarian-Cancer\/Detection-Diagnosis-Staging\/Survival-Rates.Html"},{"key":"1806_CR6","unstructured":"American Cancer Society. Uterine cancer survival rate: survival rates for endometrial cancer. Accessed [December 15, 2025]. Available at: https:\/\/Www.Cancer.Org\/Cancer\/Types\/Endometrial-Cancer\/Detection-Diagnosis-Staging\/Survival-Rates.Html"},{"key":"1806_CR7","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","volume":"388","author":"RN Eskander","year":"2023","unstructured":"Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023;388:2159\u201370. https:\/\/doi.org\/10.1056\/NEJMoa2302312.","journal-title":"N Engl J Med"},{"key":"1806_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","volume":"391","author":"I Vergote","year":"2024","unstructured":"Vergote I, Gonz\u00e1lez-Mart\u00edn A, Fujiwara K, Kalbacher E, Bagam\u00e9ri A, Ghamande S, Lee J-Y, Banerjee S, Maluf FC, Lorusso D, et al. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. N Engl J Med. 2024;391:44\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2313811.","journal-title":"N Engl J Med"},{"key":"1806_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody Drug Conjugate: The Biological Missile for Targeted Cancer Therapy. Signal Transduct Target Ther. 2022;7:93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Signal Transduct Target Ther"},{"key":"1806_CR10","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE, Garc\u00eda Y, Banerjee S, Lorusso D, Lee J-Y, Moroney JW, Colombo N, Roszak A, et al. Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023;389:2162\u201374. https:\/\/doi.org\/10.1056\/NEJMoa2309169.","journal-title":"N Engl J Med"},{"key":"1806_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/genesandcancer.40","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B. Trop2 and Its Overexpression in Cancers: Regulation and Clinical\/Therapeutic Implications. Genes Cancer. 2015;6:84\u2013105. https:\/\/doi.org\/10.18632\/genesandcancer.40.","journal-title":"Genes Cancer"},{"key":"1806_CR12","unstructured":"The Human Protein Atlas. (n.d.). TACSTD2 RNA expression summary - the human protein atlas. Accessed December 20, 2025, from Https:\/\/ https:\/\/Www.Proteinatlas.Org\/ENSG00000184292-TACSTD2\/Summary\/Rna"},{"key":"1806_CR13","doi-asserted-by":"publisher","first-page":"951589","DOI":"10.3389\/fonc.2022.951589","volume":"12","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Yuan X, Tian Q, Huang X, Chen Y, Pu Y, Long H, Xu M, Ji Y, Xie J, et al. Preclinical Profiles of SKB264, a Novel Anti-TROP2 Antibody Conjugated to Topoisomerase Inhibitor, Demonstrated Promising Antitumor Efficacy Compared to IMMU-132. Front Oncol. 2022;12:951589. https:\/\/doi.org\/10.3389\/fonc.2022.951589.","journal-title":"Front Oncol"},{"key":"1806_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41571-025-01022-0","volume":"22","author":"D Killock","year":"2025","unstructured":"Killock D. Sacituzumab Tirumotecan Improves OS in mTNBC. Nat Rev Clin Oncol. 2025;22:382\u2013382. https:\/\/doi.org\/10.1038\/s41571-025-01022-0.","journal-title":"Nat Rev Clin Oncol"},{"key":"1806_CR15","doi-asserted-by":"publisher","unstructured":"Fang W, Wu L, Meng X, Yao Y, Zuo W, Yao W, Xie Y, Zhang Y, Cui J, Zhang Y, et al. Sacituzumab Tirumotecan in EGFR-TKI\u2013Resistant, EGFR -Mutated Advanced NSCLC. N Engl J Med. 2025;NEJMoa2512071. https:\/\/doi.org\/10.1056\/NEJMoa2512071.","DOI":"10.1056\/NEJMoa2512071"},{"key":"1806_CR16","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.3390\/ijerph17134639","volume":"17","author":"C Wojtyla","year":"2020","unstructured":"Wojtyla C, Ciebiera M, Kowalczyk D, Panek G. Cervical Cancer Mortality in East-Central European Countries. Int J Environ Res Public Health. 2020;17:4639. https:\/\/doi.org\/10.3390\/ijerph17134639.","journal-title":"Int J Environ Res Public Health"},{"key":"1806_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ygyno.2024.04.022","volume":"187","author":"Y Chiba","year":"2024","unstructured":"Chiba Y, Kojima Y, Yazaki S, Yoshida H, Takamizawa S, Kitadai R, Saito A, Okuma HS, Nishikawa T, Shimoi T, et al. Trop-2 Expression and the Tumor Immune Microenvironment in Cervical Cancer. Gynecol Oncol. 2024;187:51\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2024.04.022.","journal-title":"Gynecol Oncol"},{"key":"1806_CR18","doi-asserted-by":"publisher","first-page":"e75864","DOI":"10.1371\/journal.pone.0075864","volume":"8","author":"T Liu","year":"2013","unstructured":"Liu T, Liu Y, Bao X, Tian J, Liu Y, Yang X. Overexpression of TROP2 Predicts Poor Prognosis of Patients with Cervical Cancer and Promotes the Proliferation and Invasion of Cervical Cancer Cells by Regulating ERK Signaling Pathway. PLoS ONE. 2013;8:e75864. https:\/\/doi.org\/10.1371\/journal.pone.0075864.","journal-title":"PLoS ONE"},{"key":"1806_CR19","doi-asserted-by":"publisher","first-page":"100481","DOI":"10.1016\/j.ijgc.2024.100481","volume":"35","author":"L-C Horn","year":"2025","unstructured":"Horn L-C, Wolf B, H\u00f6hn AK, Hiller R, Brambs CE. Trop-2 Expression In Cervical Carcinoma (CX) - A Possible Target For The Antibody Drug Conjugate Sacituzumab. Int J Gynecol Cancer. 2025;35:100481. https:\/\/doi.org\/10.1016\/j.ijgc.2024.100481.","journal-title":"Int J Gynecol Cancer"},{"key":"1806_CR20","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","volume":"385","author":"N Colombo","year":"2021","unstructured":"Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Ya\u00f1ez E, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385:1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa2112435.","journal-title":"N Engl J Med"},{"key":"1806_CR21","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1200\/JCO.23.00720","volume":"41","author":"I Vergote","year":"2023","unstructured":"Vergote I, Van Nieuwenhuysen E, O\u2019Cearbhaill RE, Westermann A, Lorusso D, Ghamande S, Collins DC, Banerjee S, Mathews CA, Gennigens C, et al. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205\/GOG-3024\/ENGOT-Cx8 Study. J Clin Oncol. 2023;41:5536\u201349. https:\/\/doi.org\/10.1200\/JCO.23.00720.","journal-title":"J Clin Oncol"},{"key":"1806_CR22","doi-asserted-by":"publisher","unstructured":"D\u2019Amico L, Menzel U, Prummer M, M\u00fcller P, Buchi M, Kashyap A, Haessler U, Yermanos A, G\u00e9bleux R, Briendl M, et al. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J Immunother Cancer. 2019;7. https:\/\/doi.org\/10.1186\/s40425-018-0464-1.","DOI":"10.1186\/s40425-018-0464-1"},{"key":"1806_CR23","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","volume":"77","author":"J Rios-Doria","year":"2017","unstructured":"Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, Chen C, Strout P, Mulgrew K, McGlinchey K, et al. Antibody\u2013Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. Cancer Res. 2017;77:2686\u201398. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2854.","journal-title":"Cancer Res"},{"key":"1806_CR24","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","volume":"17","author":"TN Iwata","year":"2018","unstructured":"Iwata TN, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T. A HER2-Targeting Antibody\u2013Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Mol Cancer Ther. 2018;17:1494\u2013503. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0749.","journal-title":"Mol Cancer Ther"},{"key":"1806_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10549-021-06384-4","volume":"191","author":"L Huang","year":"2022","unstructured":"Huang L, Wang R, Xie K, Zhang J, Tao F, Pi C, Feng Y, Gu H, Fang J. A HER2 Target Antibody Drug Conjugate Combined with Anti-PD-(L)1 Treatment Eliminates hHER2\u2009+\u2009Tumors in hPD-1 Transgenic Mouse Model and Contributes Immune Memory Formation. Breast Cancer Res Treat. 2022;191:51\u201361. https:\/\/doi.org\/10.1007\/s10549-021-06384-4.","journal-title":"Breast Cancer Res Treat"},{"key":"1806_CR26","doi-asserted-by":"crossref","unstructured":"Wu X, Wang J, An R et al. Efficacy and safety of Sacituzumab Tirumotecan (Sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Presented at: European Society for Medical Oncology (ESMO) Congress 2024; September 15, 2024; Lugano, Switzerland. Abstract 716MO.","DOI":"10.1016\/j.annonc.2024.08.778"},{"key":"1806_CR27","doi-asserted-by":"publisher","unstructured":"Wang D, Yao W, Wang S, Zhang K, An R, Li B, Wang K, Li J, Wang F, Lee J-Y, et al. 1168P Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT) Monotherapy in Advanced\/Metastatic Cervical Cancer: Results from a Phase I\/II Study (MK-2870-001\/KL264-01). Ann Oncol. 2025;36. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.1804.","DOI":"10.1016\/j.annonc.2025.08.1804"},{"key":"1806_CR28","doi-asserted-by":"publisher","first-page":"100497","DOI":"10.1016\/j.ijgc.2024.100497","volume":"35","author":"R Salani","year":"2025","unstructured":"Salani R, Lindemann K, Lin Z, Nishio S, Oaknin A, Kurtz J-E, Valabrega G, C\u00e1ceres MV, Harter P, Gilbert L, et al. TroFuse-020\/GOG-3101\/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician\u2019s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer. Int J Gynecol Cancer. 2025;35:100497. https:\/\/doi.org\/10.1016\/j.ijgc.2024.100497.","journal-title":"Int J Gynecol Cancer"},{"key":"1806_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial Ovarian Cancer: Evolution of Management in the Era of Precision Medicine. CA Cancer J Clin. 2019;69:280\u2013304. https:\/\/doi.org\/10.3322\/caac.21559.","journal-title":"CA Cancer J Clin"},{"key":"1806_CR30","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41416-022-02031-x","volume":"128","author":"HJ Bax","year":"2023","unstructured":"Bax HJ, Chauhan J, Stavraka C, Santaolalla A, Osborn G, Khiabany A, Grandits M, L\u00f3pez-Abente J, Palhares LCGF, Chan Wah Hak C, et al. Folate Receptor Alpha in Ovarian Cancer Tissue and Patient Serum Is Associated with Disease Burden and Treatment Outcomes. Br J Cancer. 2023;128:342\u201353. https:\/\/doi.org\/10.1038\/s41416-022-02031-x.","journal-title":"Br J Cancer"},{"key":"1806_CR31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000522206","volume":"89","author":"D Dum","year":"2022","unstructured":"Dum D, Taherpour N, Menz A, H\u00f6flmayer D, V\u00f6lkel C, Hinsch A, Gorbokon N, Lennartz M, Hube-Magg C, Fraune C, et al. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. Pathobiol J Immunopathol Mol Cell Biol. 2022;89:245\u201358. https:\/\/doi.org\/10.1159\/000522206.","journal-title":"Pathobiol J Immunopathol Mol Cell Biol"},{"key":"1806_CR32","doi-asserted-by":"publisher","unstructured":"Wang D, Wang K, An R, Yu G, Zhang K, Wang D, Jiang K, Gao Y, Cheng Y, Liu Y, et al. 715MO Safety and efficacy of Sacituzumab Tirumotecan (Sac-TMT) in Patients (Pts) with previously treated advanced Endometrial Carcinoma (EC) and Ovarian Cancer (OC) from a phase II study. Ann Oncol. 2024;35. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.777.","DOI":"10.1016\/j.annonc.2024.08.777"},{"key":"1806_CR33","doi-asserted-by":"publisher","first-page":"101997","DOI":"10.1016\/j.ijgc.2025.101997","volume":"35","author":"MDS Lightfoot","year":"2025","unstructured":"Lightfoot MDS, Rubinstein MM, Monk BJ, Eskander RN, Lutz K, Moore KN, Herzog TJ, Pothuri B. Oral Mucositis Associated with Antibody-Drug Conjugates in Gynecologic Oncology: Strategies for Prevention and Treatment. Int J Gynecol Cancer. 2025;35:101997. https:\/\/doi.org\/10.1016\/j.ijgc.2025.101997.","journal-title":"Int J Gynecol Cancer"},{"key":"1806_CR34","doi-asserted-by":"publisher","unstructured":"Giornelli GH, Mand\u00f3 PA. Theoretical view of ovarian cancer relapse. Eur Med J. 2017;128\u201335. https:\/\/doi.org\/10.33590\/emj\/10312894.","DOI":"10.33590\/emj\/10312894"},{"key":"1806_CR35","doi-asserted-by":"publisher","unstructured":"Zhang Y, Su-Feher L, Lin K, Mocci S, Komatsubara KM, Iqbal S, Odegard J. Trop-2 expression and its prognostic impact on endometrial cancer: a real-world data analysis. J Clin Oncol. 2025;43. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e17624.","DOI":"10.1200\/JCO.2025.43.16_suppl.e17624"},{"key":"1806_CR36","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1097\/IGC.0b013e318228f6da","volume":"21","author":"E Bignotti","year":"2011","unstructured":"Bignotti E, Ravaggi A, Romani C, Falchetti M, Lonardi S, Facchetti F, Pecorelli S, Varughese J, Cocco E, Bellone S, et al. Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma: Implications for Immunotherapy with hRS7, a Humanized Anti-Trop-2 Monoclonal Antibody. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2011;21:1613\u201321. https:\/\/doi.org\/10.1097\/IGC.0b013e318228f6da.","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"1806_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ygyno.2025.04.590","volume":"197","author":"S Moufarrij","year":"2025","unstructured":"Moufarrij S, Dopeso H, Brown DN, Green H, Gill K, Tengelin J, Brodeur MN, Zammarrelli WA, Varice N, Wu M, et al. TROP2 Expression and Therapeutic Targeting in Uterine Carcinosarcoma. Gynecol Oncol. 2025;197:129\u201338. https:\/\/doi.org\/10.1016\/j.ygyno.2025.04.590.","journal-title":"Gynecol Oncol"},{"key":"1806_CR38","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ygyno.2019.11.018","volume":"156","author":"C Han","year":"2020","unstructured":"Han C, Perrone E, Zeybek B, Bellone S, Tymon-Rosario J, Altwerger G, Menderes G, Feinberg J, Haines K, Muller Karger ME, et al. In Vitro and in Vivo Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Uterine Serous Carcinoma. Gynecol Oncol. 2020;156:430\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2019.11.018.","journal-title":"Gynecol Oncol"},{"key":"1806_CR39","doi-asserted-by":"publisher","first-page":"101951","DOI":"10.1016\/j.gore.2025.101951","volume":"61","author":"S-Y Lin","year":"2025","unstructured":"Lin S-Y, Chang C-T, Wu R-C, Lai C-R, Chen Y-J. Human Epidermal Growth Factor Receptor-2, Nectin-4, and Trophoblast Cell Surface Antigen-2 Expression in Endometrial Carcinosarcoma. Gynecol Oncol Rep. 2025;61:101951. https:\/\/doi.org\/10.1016\/j.gore.2025.101951.","journal-title":"Gynecol Oncol Rep"},{"key":"1806_CR40","doi-asserted-by":"publisher","first-page":"418","DOI":"10.4103\/IJPM.IJPM_783_19","volume":"63","author":"S Celik","year":"2020","unstructured":"Celik S, \u00c7elik \u00d6. Can TROP2 Be Used as a Prognostic Marker in Endometrioid Endometrial Carcinoma? Indian J Pathol Microbiol. 2020;63:418. https:\/\/doi.org\/10.4103\/IJPM.IJPM_783_19.","journal-title":"Indian J Pathol Microbiol"},{"key":"1806_CR41","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","volume":"388","author":"MR Mirza","year":"2023","unstructured":"Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Nov\u00e1k Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388:2145\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2216334.","journal-title":"N Engl J Med"},{"key":"1806_CR42","unstructured":"Yang Z, Wang D, Yao W et al. Efficacy and safety of Sacituzumab Tirumotecan (Sac\u2013TMT) monotherapy in advanced\/metastatic cervical cancer: results from a phase I\/II Study (MK\u20132870\u2013001\/KL264\u201301). Poster presented at: European Society for Medical Oncology (ESMO) congress 2025; October 18 2025; Berlin, Germany. Abstract #1168P."},{"key":"1806_CR43","doi-asserted-by":"publisher","first-page":"S592","DOI":"10.1016\/j.annonc.2024.08.2153","volume":"35","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Mirza MR, Martin-Babau J, Bologna A, Barretina Ginesta MP, Marm\u00e9 F, Wampfler J, Cibula D, Zhu J, Hasegawa K, et al. 793TiP A Phase III, Randomized, Open-Label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT) Monotherapy vs Treatment of Physician\u2019s Choice Chemotherapy in Patients with Endometrial Cancer Who Have Received Prior Chemotherapy and Immunotherapy: ENGOT-En23\/GOG-3095\/MK-2870-005. Ann Oncol. 2024;35:S592. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2153.","journal-title":"Ann Oncol"},{"key":"1806_CR44","doi-asserted-by":"publisher","first-page":"101679","DOI":"10.1016\/j.gore.2025.101679","volume":"57","author":"ENB Pham","year":"2025","unstructured":"Pham ENB, Van Den Berg CB, Boere I, De Geus V, Haagsma JA, Maliepaard M, Mens JWM, Groenendijk FH, Van Beekhuizen HJ. Quality of Life and Survival in Patients with Uterine Carcinosarcoma: A Tertiary Center Observational Study. Gynecol Oncol Rep. 2025;57:101679. https:\/\/doi.org\/10.1016\/j.gore.2025.101679.","journal-title":"Gynecol Oncol Rep"},{"key":"1806_CR45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ygyno.2025.06.017","volume":"199","author":"M Greenman","year":"2025","unstructured":"Greenman M, Bellone S, Demirkiran C, Hartwich TMP, Ettorre VM, McNamara B, Sethi N, Santin NG, Palmieri L, Yang-Hartwich Y, et al. Datopotamab Deruxtecan, a Novel TROP2-Tareting Antibody-Drug Conjugate with a Topoisomerase I Inhibitor Payload, Shows Preclinical Activity against Primary and Metastatic Uterine and Ovarian TROP2 over-Expressing Carcinosarcoma. Gynecol Oncol. 2025;199:64\u201371. https:\/\/doi.org\/10.1016\/j.ygyno.2025.06.017.","journal-title":"Gynecol Oncol"},{"key":"1806_CR46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","volume":"22","author":"A Kopp","year":"2023","unstructured":"Kopp A, Hofsess S, Cardillo TM, Govindan SV, Donnell J, Thurber GM. Antibody\u2013Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release. Mol Cancer Ther. 2023;22:102\u201311. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0375.","journal-title":"Mol Cancer Ther"},{"key":"1806_CR47","doi-asserted-by":"publisher","first-page":"e28385","DOI":"10.1016\/j.heliyon.2024.e28385","volume":"10","author":"FM Schipilliti","year":"2024","unstructured":"Schipilliti FM, Drittone D, Mazzuca F, La Forgia D, Guven DC, Rizzo A. Datopotamab Deruxtecan: A Novel Antibody Drug Conjugate for Triple-Negative Breast Cancer. Heliyon. 2024;10:e28385. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28385.","journal-title":"Heliyon"},{"key":"1806_CR48","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1186\/s40001-025-03538-8","volume":"30","author":"J Huang","year":"2025","unstructured":"Huang J, Huang T, Guo J, Hu K, Zhou H. The Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) in Advanced Solid Tumors: A Systematic Review and Meta-Analysis. Eur J Med Res. 2025;30:1265. https:\/\/doi.org\/10.1186\/s40001-025-03538-8.","journal-title":"Eur J Med Res"},{"key":"1806_CR49","doi-asserted-by":"publisher","first-page":"S547","DOI":"10.1016\/j.annonc.2024.08.776","volume":"35","author":"A Oaknin","year":"2024","unstructured":"Oaknin A, Ang JE, Rha SY, Yonemori K, Kristeleit R, Lin C-C, Satoh T, Garcia PE, Sendur MAN, Rodr\u00edguez LM, et al. 714MO Datopotamab Deruxtecan (Dato-DXd) in Patients with Endometrial (EC) or Ovarian Cancer (OC): Results from the Phase II TROPION-PanTumor03 Study. Ann Oncol. 2024;35:S547\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.776.","journal-title":"Ann Oncol"},{"key":"1806_CR50","doi-asserted-by":"publisher","unstructured":"Eskander RN, Corr B, Cibula D, Tan DSP, Cloven N, Guerra E, Hasegawa K, Myers T, You B, Makker V, et al. A randomized, phase III study of sacituzumab govitecan versus treatment of the physician\u2019s choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104\/ENGOT-En26\/APGOT-EN2). Int J Gynecol Cancer. 2025;102654. https:\/\/doi.org\/10.1016\/j.ijgc.2025.102654.","DOI":"10.1016\/j.ijgc.2025.102654"},{"key":"1806_CR51","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1200\/JCO.23.02767","volume":"42","author":"AD Santin","year":"2024","unstructured":"Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin K-W, et al. Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42:3421\u20139. https:\/\/doi.org\/10.1200\/JCO.23.02767.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1806_CR52","doi-asserted-by":"publisher","unstructured":"Dacoregio MI, Michelon I, Ernesto doR, Castro C, de Cezar F, de Rossato G, Ravani LV, Vilbert M, Barros Costa RL. Safety profile of sacituzumab govitecan in patients with breast cancer: a systematic review and meta-analysis. Breast 2025;79:103853. https:\/\/doi.org\/10.1016\/j.breast.2024.103853","DOI":"10.1016\/j.breast.2024.103853"},{"key":"1806_CR53","doi-asserted-by":"publisher","first-page":"e1435","DOI":"10.1093\/oncolo\/oyae177","volume":"29","author":"GK Dy","year":"2024","unstructured":"Dy GK, Farooq AV, Kang JJ. Ocular Adverse Events Associated with Antibody-Drug Conjugates for Cancer: Evidence and Management Strategies. Oncologist. 2024;29:e1435\u201351. https:\/\/doi.org\/10.1093\/oncolo\/oyae177.","journal-title":"Oncologist"},{"key":"1806_CR54","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.25251\/12yhc207","volume":"9","author":"L Kaufman","year":"2025","unstructured":"Kaufman L, Dulmage B, Gatti-Mays M. Antibody-Drug Conjugate Induced Hair Loss Responds to Minoxidil: A Case Report. SKIN J Cutan Med. 2025;9:2528\u201332. https:\/\/doi.org\/10.25251\/12yhc207.","journal-title":"SKIN J Cutan Med"},{"key":"1806_CR55","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, et al. Biomarker Analyses in the Phase III ASCENT Study of Sacituzumab Govitecan versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. Ann Oncol. 2021;32:1148\u201356. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.002.","journal-title":"Ann Oncol"},{"key":"1806_CR56","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","volume":"43","author":"M-J Ahn","year":"2025","unstructured":"Ahn M-J, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, P\u00e9rol M, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol Off J Am Soc Clin Oncol. 2025;43:260\u201372. https:\/\/doi.org\/10.1200\/JCO-24-01544.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1806_CR57","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1200\/JCO.24.00733","volume":"42","author":"LG Paz-Ares","year":"2024","unstructured":"Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, Girard N, Patel VM, Takahama T, Owen SP, et al. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42:2860\u201372. https:\/\/doi.org\/10.1200\/JCO.24.00733.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1806_CR58","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1200\/JCO.2024.42.16_suppl.104","volume":"42","author":"B Xu","year":"2024","unstructured":"Xu B, Yin Y, Fan Y, Ouyang Q, Song L, Wang X, Li W, Li M, Yan X, Wang S, et al. Sacituzumab Tirumotecan (SKB264\/MK-2870) in Patients (Pts) with Previously Treated Locally Recurrent or Metastatic Triple-Negative Breast Cancer (TNBC): Results from the Phase III OptiTROP-Breast01 Study. J Clin Oncol. 2024;42:104\u2013104. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.104.","journal-title":"J Clin Oncol"},{"key":"1806_CR59","doi-asserted-by":"publisher","unstructured":"Ramos C, Spatial. PK\/PD profiling in human ex vivo tumor slices to identify exposure-limited niches driving heterogeneous response to a TROP2-targeting ADC in NSCLC. J Clin Oncol. 2026;44. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.e15040.","DOI":"10.1200\/JCO.2026.44.16_suppl.e15040"},{"key":"1806_CR60","doi-asserted-by":"publisher","first-page":"8637","DOI":"10.1200\/JCO.2025.43.16_suppl.8637","volume":"43","author":"A Li","year":"2025","unstructured":"Li A, Zhu HL, Wu K, Yu Z, Liu S, Yang X, Zhang L, Zhou Y, Hong S. Efficacy and Omics-Based Insights of TROP2 ADC in Non\u2013Small Cell Lung Cancer with or without Actionable Genomic Alterations (AGAs). J Clin Oncol. 2025;43:8637\u20138637. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8637.","journal-title":"J Clin Oncol"},{"key":"1806_CR61","doi-asserted-by":"publisher","unstructured":"Planchard D, Cozic N, Mosele MF, Corcos N, Le Bescond L, Pradat Y, Ghigna MR, Nachabeh G, Alfaro A, Catelain C, et al. Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study. Cancer Cell. 2026;S1535610826001716. https:\/\/doi.org\/10.1016\/j.ccell.2026.03.017.","DOI":"10.1016\/j.ccell.2026.03.017"},{"key":"1806_CR62","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/PAI.0000000000001311","volume":"34","author":"M He","year":"2026","unstructured":"He M, Chan NNN, Liu M, Robbins CJ, Bates K, Benanto J, Col\u00f3n-Cartagena L, Kahila M, Zhan H, Krishnamurti U, et al. Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score. Appl Immunohistochem Mol Morphol AIMM. 2026;34:143\u201354. https:\/\/doi.org\/10.1097\/PAI.0000000000001311.","journal-title":"Appl Immunohistochem Mol Morphol AIMM"},{"key":"1806_CR63","doi-asserted-by":"publisher","first-page":"e012265","DOI":"10.1136\/jitc-2025-012265","volume":"14","author":"B Wu","year":"2026","unstructured":"Wu B, Thant W, Bitman E, Liu T, Liu J, Paschalis EI, Patel BK, Nawrocki C, Xu KH, Nieman LT, et al. TROP2\/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer. J Immunother Cancer. 2026;14:e012265. https:\/\/doi.org\/10.1136\/jitc-2025-012265.","journal-title":"J Immunother Cancer"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01806-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01806-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01806-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:10:15Z","timestamp":1782119415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01806-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1806"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01806-2","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FZ has received honoraria for lectures and has served in an advisory role for Astra-Zeneca, Daiichi, Eli-Lilly, Merck, MSD, Novartis, Pfizer, and Roche. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}